论文部分内容阅读
本文对一种叶绿素衍生物(CHDM)作为光动力抗肿瘤药物进行初步研究,为光动力治疗肿瘤寻找理想的光敏剂。通过MTT实验对CHDM对人胆管癌QBC-939细胞的暗毒性和光毒性进行了评价。在体内,通过接种人胆管癌QBC-939细胞于裸小鼠皮下,建立移植肿瘤模型,CHDM以5 mg/kg的剂量,采用尾静脉注射,再以波长650 nm的He-Ne激光照射肿瘤局部,观察光动力治疗后肿瘤的生长速度和形态变化,并测定肿瘤大小。在体外,CHDM具有极低的暗毒性,在光照条件下能有效地抑制QBC-939细胞生长,且光动力效应具有药物浓度和光照剂量依赖性。在体内,接受CHDM光动力治疗的肿瘤生长速度明显减慢,肿瘤体积显著变小。实验研究显示CHDM有望成为新型光动力抗肿瘤药物,值得进一步研究。
In this paper, a chlorophyll derivative (CHDM) as a photodynamic anti-tumor drug to conduct a preliminary study for the photodynamic therapy of cancer looking for the ideal photosensitizer. The dark toxicity and phototoxicity of CHDM on human cholangiocarcinoma QBC-939 cells were evaluated by MTT assay. In vivo, a transplanted tumor model was established by inoculation of human cholangiocarcinoma QBC-939 cells in nude mice subcutaneously. CHDM was injected into the tail vein at a dose of 5 mg / kg and then irradiated by He-Ne laser with a wavelength of 650 nm , Observe the tumor growth rate and morphological changes after photodynamic therapy, and determine the size of the tumor. In vitro, CHDM has very low dark toxicity, can effectively inhibit the growth of QBC-939 cells under light conditions, and the photodynamic effects of drug concentration and light dose-dependent. In vivo, the tumor growth rate of CHDM photodynamic therapy significantly slowed down, the tumor volume was significantly smaller. Experimental studies have shown CHDM is expected to become a new type of photodynamic anti-tumor drugs, it is worth further study.